38
Participants
Start Date
August 19, 2022
Primary Completion Date
November 27, 2023
Study Completion Date
March 6, 2026
Mavacamten
Specified dose on specified days
Local Institution - 0003, Fuchu-Shi
Local Institution - 0020, Uwajima
Local Institution - 0026, Himeji-Shi
Local Institution - 0016, Kobe
Local Institution - 0017, Tsukuba
Local Institution - 0023, Kanazawa
Local Institution - 0019, Yokohama
Local Institution - 0015, Nankoku-shi
Local Institution - 0028, Tsu
Local Institution - 0027, Sendai
Local Institution - 0014, Suita
Local Institution - 0011, Suita-Shi
Local Institution - 0012, Hamamatsu
Local Institution - 0010, Bunkyo-Ku
Local Institution - 0009, Chuo-Ku
Local Institution - 0001, Itabashi-Ku
Local Institution - 0007, Koto-Ku
Local Institution - 0005, Shinjuku-Ku
Local Institution - 0013, Shinjuku-ku
Local Institution - 0018, Osaka
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY